Kite publishes Phase II data for Yescarta in treating B-cell lymphoma

Gilead Sciences company Kite published Phase II data for Yescarta (axicabtagene ciloleucel) for treating relapsed/refractory (R/R) large B-cell lymphoma (LBCL) in Nature Medicine.

Yescarta is CD-19-directed autologous chimeric antigen receptor (CAR)-T cell therapy. It was first approved by the US Food and Drug Administration (FDA) for large B-cell lymphoma, primary mediastinal large B-cell lymphoma, high-grade B-cell lymphoma, and diffuse large B-cell lymphoma (DLBCL) arising from follicular lymphoma.